Flagship Pioneering’s Post

Leveraging living human cells to fight disease has already proven to be incredibly powerful in hematological oncology and holds huge promise, e.g. in devastating autoimmune diseases. However, autologous cell therapies are difficult to make, and 7 years after the first approvals, only about 35,000 patients have been treated with all approved products combined. We need truly breakthrough innovations to bring such therapies to all patients in need. What if.. we build targeted platforms to better engineer cells directly in vivo - skipping ex vivo cell manufacturing alltogether?! Read my short viewpoint article summarizing my thoughts. https://lnkd.in/gnZGpzvB

Mirai Bio President and COO, Jens H. Vogel, Ph.D. captures the scalability challenges facing #celltherapies in this Cell & Gene Therapy Insights article, exploring innovative solutions like in vivo engineering to expand patient access and streamline production.

Our highly anticipated cell therapy webinar is just one week away, so secure your spot before it's too late ⏳ https://ter.li/9bwzoc Get ready to explore how allogeneic cell therapies are making waves with scalable and innovative alternatives to traditional autologous treatments. Here’s a sneak peek: 💸 Total deal value involving allogeneic cell therapies in 2023 was $981 million, but this year we’ve already surpassed that investment! 🔬 130 allogeneic trials have their end dates this year, providing a wealth of new data and insights. 🧪 Over 440 allogeneic trials are currently recruiting participants. Find out more about these promising developments. Our expert panel will dive deep into these exciting advancements. Don’t miss the chance to stay ahead of the curve and unlock the potential of cutting-edge allogeneic solutions in oncology and beyond. #CellTherapy #Allogeneic #AllogeneicTherapies #MarketInsights Hanson Wade Intelligence

From cell therapies to treat solid tumors to a growing number of allogeneic cell therapies coming through the clinical pipeline, there is plenty to be excited about in the cell therapy space as we head into 2025. In this segment from “Executive Roundtable: Cell Therapy Predictions For 2025 And Beyond,” our panelists Kevin Caldwell, Hamid Khoja, Ph.D., and Robert Williamson discuss promising innovations in the field and share what data and approvals they look forward to seeing in 2025. https://lnkd.in/eXTRR-Uc

ImmunityBio is investigating immunotherapy and cell therapy combinations with the goal of improving outcomes for patients with refractory #NonHodgkinLymphoma. Learn more about our NHL clinical trial here: https://lnkd.in/gdYxczbc

"Singapore has recently seen a biotech resurgence in the form of cell therapy and cell science-related start-ups." "This resurgence is undoubtedly inspired in large part by recent clinical successes using T-cell immunotherapy and associated technologies, particularly in the treatment of cancers and autoimmune diseases." -> https://shorturl.at/1Ho3P #CarTcells #cartcelltherapy #cancertherapy #biotechstocks #biotech #undervalued #immunotherapy #nasdaq #nasdaqstocks #preclinical #gdtc #investing

Carcinomas account for ~90% of cancers. This is why the recent FDA approval of TIL therapy is changing the field of cell therapy. In this podcast, Jason Bock talks with Daniel Levine about this achievement and what is on the horizon with the brilliant next generation TILs in development and in the clinic. #biotech #celltherapy #TILtherapy #endcancer https://lnkd.in/et-A5hUe

Are you stressed about supply chain risks? Cell therapy manufacturers are finding ways to reduce vulnerability — and we’re here to help. Discover one company's solution in our latest case study. https://lnkd.in/efQDr2Eb #celltherapy #supplychain #riskmanagement

While uptake has been limited, cell therapy’s impact in cancer care is growing, and biotech companies have continued to invest in ways to improve it, such as through “off-the-shelf” options or by using different types of immune cells. Explore the current market for cancer cell therapies and what biotechs are working on next. https://lnkd.in/dR-ntd3m

Peripheral blood: A viable alternative in cell therapy? This case study suggests yes! Learn how a manufacturer successfully used peripheral blood as starting material in CAR-T production, gaining flexibility and cost savings. https://lnkd.in/efQDr2Eb #celltherapy #innovation #materialssourcing